An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim resultsVignesh T. Packiam, Gary D. Steinberg, Igor Dumbadze et al.|Urologic Oncology Seminars and Original Investigations|2017Cited by 250
MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIALVignesh T. Packiam, Gary D. Steinberg, Daniel A. Barocas et al.|The Journal of Urology|2019Cited by 13
MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)Vignesh T. Packiam, Gary D. Steinberg, Alexa Campanile et al.|The Journal of Urology|2016Cited by 9
LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIALVignesh T. Packiam, Gary D. Steinberg, Daniel A. Barocas et al.|The Journal of Urology|2018Cited by 4